| Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer (NCT01163084) | National Cancer Institute (NCI) | 2010-07-09 |
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma (NCT01089101) | National Cancer Institute (NCI) | 2010-07-07 |
| Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients (NCT01424878) | National Cancer Institute (NCI) | 2010-07-05 |
| RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01175343) | National Cancer Institute (NCI) | 2010-07-01 |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin (NCT01200797) | National Cancer Institute (NCI) | 2010-07-01 |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia (NCT01059786) | National Cancer Institute (NCI) | 2010-07-01 |
| Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer (NCT01149083) | National Cancer Institute (NCI) | 2010-06-30 |
| Genetics of Mammographic Appearances and Patterns (The GenMap Study) (NCT01160510) | National Cancer Institute (NCI) | 2010-06-24 |
| Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma (NCT01145495) | National Cancer Institute (NCI) | 2010-06-15 |
| Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study (NCT01139476) | National Cancer Institute (NCI) | 2010-06-15 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia (NCT01139970) | National Cancer Institute (NCI) | 2010-06-04 |
| Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy (NCT01160458) | National Cancer Institute (NCI) | 2010-06-02 |
| Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer (NCT01195415) | National Cancer Institute (NCI) | 2010-06-01 |
| Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors (NCT01145456) | National Cancer Institute (NCI) | 2010-06-01 |
| Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT01141244) | National Cancer Institute (NCI) | 2010-06-01 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (NCT01159301) | National Cancer Institute (NCI) | 2010-06-01 |
| A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy (NCT01141569) | National Cancer Institute (NCI) | 2010-06-01 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (NCT01154452) | National Cancer Institute (NCI) | 2010-06-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer (NCT01160445) | National Cancer Institute (NCI) | 2010-06-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer (NCT01151449) | National Cancer Institute (NCI) | 2010-06-01 |
| Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye (NCT01143402) | National Cancer Institute (NCI) | 2010-06-01 |
| Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (NCT01145430) | National Cancer Institute (NCI) | 2010-06-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01132820) | National Cancer Institute (NCI) | 2010-06-01 |
| Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer (NCT01142401) | National Cancer Institute (NCI) | 2010-05-26 |
| Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) (NCT01196520) | National Cancer Institute (NCI) | 2010-05-25 |
| A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum (NCT01134601) | National Cancer Institute (NCI) | 2010-05-24 |
| Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01130506) | National Cancer Institute (NCI) | 2010-05-17 |
| A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors (NCT01130623) | National Cancer Institute (NCI) | 2010-05-10 |
| A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas (NCT01132911) | National Cancer Institute (NCI) | 2010-05-10 |
| A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer (NCT01130519) | National Cancer Institute (NCI) | 2010-05-06 |
| Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (NCT01132586) | National Cancer Institute (NCI) | 2010-05-01 |
| Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia (NCT01126502) | National Cancer Institute (NCI) | 2010-05-01 |
| RO4929097 in Treating Patients With Metastatic Colorectal Cancer (NCT01116687) | National Cancer Institute (NCI) | 2010-05-01 |
| ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors (NCT01154426) | National Cancer Institute (NCI) | 2010-05-01 |
| Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers (NCT01021215) | National Cancer Institute (NCI) | 2010-05-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (NCT01119599) | National Cancer Institute (NCI) | 2010-05-01 |
| A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases (NCT01120288) | National Cancer Institute (NCI) | 2010-04-29 |
| Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses (NCT01194687) | National Cancer Institute (NCI) | 2010-04-27 |
| A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas (NCT01117155) | National Cancer Institute (NCI) | 2010-04-23 |
| Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) (NCT01109407) | National Cancer Institute (NCI) | 2010-04-22 |
| Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies (NCT01109394) | National Cancer Institute (NCI) | 2010-04-21 |
| Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer (NCT00979992) | National Cancer Institute (NCI) | 2010-04-19 |
| Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (NCT01076543) | National Cancer Institute (NCI) | 2010-04-15 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648) | National Cancer Institute (NCI) | 2010-04-14 |
| Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery (NCT01013649) | National Cancer Institute (NCI) | 2010-04-05 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01074411) | National Cancer Institute (NCI) | 2010-04-05 |
| Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (NCT01132573) | National Cancer Institute (NCI) | 2010-04-01 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01076556) | National Cancer Institute (NCI) | 2010-04-01 |
| Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer (NCT01105377) | National Cancer Institute (NCI) | 2010-04-01 |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma (NCT01105390) | National Cancer Institute (NCI) | 2010-04-01 |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma (NCT01093222) | National Cancer Institute (NCI) | 2010-04-01 |
| Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia (NCT01097304) | National Cancer Institute (NCI) | 2010-04-01 |
| Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... (NCT01118091) | National Cancer Institute (NCI) | 2010-04-01 |
| Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma (NCT01092182) | National Cancer Institute (NCI) | 2010-03-25 |
| Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (NCT01064648) | National Cancer Institute (NCI) | 2010-03-15 |
| A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers (NCT01086696) | National Cancer Institute (NCI) | 2010-03-09 |
| A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies (NCT01100944) | National Cancer Institute (NCI) | 2010-03-04 |
| Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment (NCT01087333) | National Cancer Institute (NCI) | 2010-03-02 |
| Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma (NCT00979862) | National Cancer Institute (NCI) | 2010-03-01 |
| Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer (NCT01077453) | National Cancer Institute (NCI) | 2010-03-01 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (NCT00955305) | National Cancer Institute (NCI) | 2010-03-01 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (NCT01088763) | National Cancer Institute (NCI) | 2010-03-01 |
| Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer (NCT00956163) | National Cancer Institute (NCI) | 2010-03-01 |
| AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma (NCT01085214) | National Cancer Institute (NCI) | 2010-03-01 |
| Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma (NCT01062425) | National Cancer Institute (NCI) | 2010-02-26 |
| A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) (NCT01090765) | National Cancer Institute (NCI) | 2010-02-23 |
| Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy (NCT00813423) | National Cancer Institute (NCI) | 2010-02-19 |
| Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer (NCT01015833) | National Cancer Institute (NCI) | 2010-02-15 |
| O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma (NCT00961220) | National Cancer Institute (NCI) | 2010-02-01 |
| Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (NCT00669734) | National Cancer Institute (NCI) | 2010-02-01 |
| Pioglitazone for Oral Premalignant Lesions (NCT00951379) | National Cancer Institute (NCI) | 2010-02-01 |
| GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery (NCT00980343) | National Cancer Institute (NCI) | 2010-02-01 |
| 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma (NCT01169350) | National Cancer Institute (NCI) | 2010-02-01 |
| Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors (NCT01076530) | National Cancer Institute (NCI) | 2010-02-01 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies (NCT01096355) | National Cancer Institute (NCI) | 2010-02-01 |
| A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) (NCT01100931) | National Cancer Institute (NCI) | 2010-02-01 |
| Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191 (NCT01086709) | National Cancer Institute (NCI) | 2010-01-27 |
| Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (NCT01051557) | National Cancer Institute (NCI) | 2010-01-27 |
| A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas (NCT01051635) | National Cancer Institute (NCI) | 2010-01-25 |
| Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma (NCT01016730) | National Cancer Institute (NCI) | 2010-01-22 |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation (NCT00984165) | National Cancer Institute (NCI) | 2010-01-19 |
| Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases (NCT01095523) | National Cancer Institute (NCI) | 2010-01-14 |
| Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer (NCT00976677) | National Cancer Institute (NCI) | 2010-01-01 |
| Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma (NCT01055314) | National Cancer Institute (NCI) | 2010-01-01 |
| Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer (NCT01313078) | National Cancer Institute (NCI) | 2010-01-01 |
| Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus (NCT01061606) | National Cancer Institute (NCI) | 2010-01-01 |
| A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma (NCT01051934) | National Cancer Institute (NCI) | 2009-12-29 |
| A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening (NCT01058148) | National Cancer Institute (NCI) | 2009-12-22 |
| Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma (NCT01041638) | National Cancer Institute (NCI) | 2009-12-21 |
| Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme (NCT01122888) | National Cancer Institute (NCI) | 2009-12-01 |
| Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy (NCT01039155) | National Cancer Institute (NCI) | 2009-12-01 |
| Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery (NCT01026792) | National Cancer Institute (NCI) | 2009-12-01 |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616) | National Cancer Institute (NCI) | 2009-12-01 |
| Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery (NCT00835679) | National Cancer Institute (NCI) | 2009-12-01 |
| Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease (NCT01036958) | National Cancer Institute (NCI) | 2009-11-25 |
| Evaluation of Skin, Colonic, and Oral Microbiome and Effect of Time and Antibiotic Treatment on Organism Diversity at Each Site (NCT01143571) | National Cancer Institute (NCI) | 2009-11-20 |
| Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing (NCT01031641) | National Cancer Institute (NCI) | 2009-11-19 |
| A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer (NCT01021059) | National Cancer Institute (NCI) | 2009-11-10 |